Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 12Terminated 3Unknown 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × folfirinox × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

NCT01688336 2017-10-06

FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
9 enrolled 14 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡